AstraZeneca Reports Robust H1 2026 Growth with 30 Regulatory Approvals and Reaffirms $80 Billion Revenue Goal for 2030

Oncology Segment Drives 15% Revenue Growth Amid Pipeline Advancements

AstraZeneca's Oncology division reported $14.124 billion in revenue for H1 2026, a 15% increase at constant exchange rates compared to the previous year. This growth was fueled by strong demand for established treatments and successful launches of newly approved therapies across various cancer types. Key products included Tagrisso, generating $3.775 billion, and Imfinzi, which achieved $3.548 billion with 29% growth due to recent label expansions and market penetration in gastrointestinal and genitourinary cancers.

The company secured eight oncology approvals in major markets during this period, including FDA clearance of Baxfendy, the first-in-class K-channel activator for hypertension, and multiple HER2-targeted approvals for Enhertu across solid tumors. Emerging oncology drugs such as Datroway and Truqap posted revenues of $98 million and $431 million respectively, while Lynparza remained stable at $1.610 billion amid increasing generic competition.

Rare Disease Segment Expands with 11% Revenue Growth and Strong Ultomiris Uptake

The Rare Disease portfolio generated $4.911 billion in H1 2026 revenue, up 11% at constant exchange rates, accounting for 16% of total company revenue. Ultomiris recorded $2.584 billion with 14% growth, driven by patient transitions from Soliris and expansion into new indications. Strensiq posted robust 40% growth to $1.053 billion, supported by increased patient demand and US adult indication launch.

Soliris revenues declined 22% to $778 million, reflecting the shift to Ultomiris. Koselugo contributed $347 million with 21% growth following expansion into adult populations. The rare disease segment's strong performance underpins AstraZeneca's medium-term revenue growth strategy.

Cardiovascular and Metabolic Division Impacted by Farxiga Patent Loss and China Pricing Policies

The Cardiovascular, Renal and Metabolism area saw revenues decline 12% to $6.089 billion at constant exchange rates, primarily due to Farxiga's loss of US exclusivity in Q2 2026 and generic competition. Farxiga revenue fell 11% to $4.042 billion, with US sales dropping 17%. Pricing pressures from China’s volume-based procurement further reduced Emerging Markets revenue by 13%.

Despite these headwinds, drugs like Crestor and Lokelma showed resilience, generating $719 million and $419 million respectively, with notable growth in Emerging Markets. Baxfendy’s recent US launch contributed $3 million in initial revenue. Brilinta and roxadustat experienced declines due to patent expirations and generic competition.

Respiratory and Immunology Segment Achieves 9% Growth Despite Generic Challenges

The Respiratory and Immunology division posted $4.750 billion in H1 2026 revenue, up 9% at constant exchange rates. Fasenra reached $1.053 billion with 12% growth, boosted by expanded indications and strong Emerging Markets performance following inclusion in China’s reimbursement list. Tezspire grew 40% to $694 million, supported by demand in severe asthma and nasal polyposis.

Breztri achieved $699 million with 17% growth and gained asthma indication approval in April 2026. Symbicort’s revenue declined 4% to $1.418 billion due to US generic competition, partially offset by Emerging Markets growth.

Regulatory Achievements and Clinical Trial Successes Mark H1 2026

Since Q4 2025, AstraZeneca secured 30 major regulatory approvals globally, including first-time authorizations for Baxfendy, Datroway, Enhertu, Etcamah, and Imfinzi across multiple indications and regions. The company also reported six positive Phase III trial results, including Imfinzi’s success in bladder cancer trials and Sonevetug’s efficacy in gastric cancer. However, the CARDIO-TTRansform trial for Wainua failed to meet its primary endpoint, representing a notable setback.

More than 20 significant trial readouts are expected over the next 18 months, underscoring AstraZeneca’s robust clinical development pipeline.

Strategic Acquisitions Bolster Oncology and Respiratory Pipelines

In July 2026, AstraZeneca announced two key deals: an exclusive worldwide license for Zegfrovy (sunvozertinib) from Dizal Pharmaceutical, involving $600 million upfront and up to $900 million in milestones, and a licensing agreement with Sino Biopharmaceutical for TQC3721, with $200 million upfront and up to $1.9 billion in milestones. These transactions expand AstraZeneca’s lung cancer and respiratory disease portfolios and strengthen its global development partnerships.

Financial Overview: Core EPS Growth Outpaces Revenue Amid Increased Operating Costs

In H1 2026, AstraZeneca’s core EPS rose 11% to $5.21 at constant exchange rates, while total revenue increased 6% to $30.672 billion. Gross margin improved to 84%, aided by favorable product mix and manufacturing efficiencies. R&D expenses grew 13% to $4.053 billion, reflecting expanded clinical trials and strategic investments. SG&A expenses increased 14% to $5.651 billion due to ongoing and planned product launches. Operating profit declined 13% to $3.164 billion, with operating margin contracting to 21%. Net finance expense was $355 million, and the reported tax rate was 10%, benefiting from deferred tax asset adjustments.

Geographic Revenue Performance: US Stable, Europe Grows, China Faces Challenges

The United States accounted for 42% of revenue at $12.890 billion, growing 8% driven by oncology and rare disease despite Farxiga’s generic erosion. Europe contributed $6.822 billion with 8% growth, supported by cancer and respiratory portfolio expansions. China’s revenue was $3.510 billion, flat in actual terms and down 5% at constant currency due to pricing pressures and generic competition. Emerging Markets excluding China grew 10% to $4.809 billion, while Rest of World regions posted 5% growth to $2.641 billion. Foreign exchange headwinds persisted, with constant currency growth exceeding reported figures across most segments.

2026 Guidance Maintained Amid Pipeline Confidence and FX Uncertainty

AstraZeneca reaffirmed its 2026 guidance, projecting mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates, assuming FX rates consistent with 2025. If FX rates from June 2026 persist through H2, reported revenue could see a low single-digit positive impact, with core EPS growth remaining stable. The core tax rate is expected between 18% and 22% for the year.

CEO Pascal Soriot emphasized confidence in the pipeline and medium-term targets despite setbacks like the Wainua trial failure. The interim dividend was raised by 3 cents to $1.06 per share, reflecting strong business momentum and cash flow.

Pipeline Updates Highlight Mixed Clinical Outcomes and Future Catalysts

H1 2026 clinical results showed both advances and challenges. Imfinzi demonstrated efficacy in bladder cancer trials, while the CARDIO-TTRansform trial for Wainua failed. AstraZeneca expects over 20 pivotal trial readouts in the next 18 months, providing significant catalysts for growth and potential label expansions. The company’s Clinical Trials Appendix offers detailed insights into ongoing programs and timelines.